The Online Investor

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Thu., Feb. 27, 2:35 PM

Slide #9. Agile Therapeutics, Inc. Secondary Offering

Company: Agile Therapeutics, Inc. (NASDAQ:AGRX)
Date announced: 2/20/2020
Shares Offered: 15,000,000
Date of Pricing: 2/21/2020
Price Per Share: $3.00
Secondary Offering Details: Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All shares being offered are to be sold by Agile Therapeutics. Agile Therapeutics intends to grant the underwriters a 30-day option to purchase an additional fifteen percent of the shares of common stock offered in the public offering. The proposed offering is subject to market and other conditions, and there can be no assurances as to whether or when the offering may be completed, or as to the actual size or terms of the offering. -updated 2/21- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced the pricing of its underwritten public offering of 15 million shares of its common stock at a public offering price of $3.00 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses payable by Agile Therapeutics, are expected to be approximately $45 million. In addition, Agile Therapeutics has granted the underwriters a 30-day option to purchase up to 2.25 million additional shares of common stock at the public offering price, less the underwriting discounts and commissions. All shares in the offering will be sold by Agile Therapeutics.

Agile Therapeutics is a women's healthcare company. Co.'s primary product candidate, Twirla, also known as AG200-15, is a once-weekly prescription combination hormonal contraceptive patch that is at the end of clinical development. Twirla is a combined hormonal contraceptives patch that contains the active ingredients ethinyl estradiol, which is a synthetic estrogen, and levonorgestrel, which is a type of progestin, a synthetic steroid hormone. Co. also has a pipeline of other transdermal contraceptive products, including AG200-ER, which is a regimen designed to allow a woman to extend the length of her cycle, and AG200-SP, which is a regimen designed to provide shorter lighter periods.
Open the AGRX Page at The Online Investor »

Company Name: 
Agile Therapeutics Inc
Website: 
www.agiletherapeutics.com
Sector: 
Drugs & Pharmaceuticals
Number of ETFs Holding AGRX: 
3
Total Market Value Held by ETFs: 
$4.89M
Total Market Capitalization: 
$211.00M
% of Market Cap. Held by ETFs: 
2.32%
 

Open the AGRX Page at The Online Investor (in a new window) »

Quotes delayed 20 minutes



Strong Buy (3.83 out of 4)
77th percentile
(ranked higher than approx. 77% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Secondary Stock Offerings Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2020, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.